MV still open to acquisition despite calling off Acron merger talks
This article was originally published in Clinica
Executive Summary
Molecular Vision (MV) announced last week that it had ceased discussions with its Swiss development partner Acrongenomics over a potential merger. The two companies had agreed in November 2007 to MV becoming a wholly-owned subsidiary of Acron and that the transaction was to be completed at the end of January. However, the deadline has since been extended twice, and while Acron acquired a 10.9% stake in MV in February 2008, a full acquisition was not completed as expected at the end of March. Dr Campbell told Clinica that by dropping the deal, both companies are able to concentrate on their respective activities "without being clouded by the takeover discussion". However, he did not reject the possibility of picking up merger discussions with Acron, or with other potential suitors, in the future. The breakdown of the merger talks will not affect the existing R&D agreement between the two companies to develop low-cost, readily portable POC diagnostics using MV's proprietary light emitting based (LEP)-based detector technology.
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.